Palliative Care Template

National After death audit (from practice held registers) revealed:

- Only 27% of patients who died were identified.
- 75% of deaths were non-cancer but only 29% were identified prior to death
- Only 42% had ACP recorded
- Patients on registers received better coordinated care


UK Policy suggests all localities introduce an EPaCCs by 2020.


Why use this template?

- Caring for patients with EoL is complex and often requires multiple professionals, this uses the same codes as District nurses and the Macmillan team use (reduce duplication)
- Printable for OOH if not on system one
- Discussion and recording of preferences leads to reduced hospital deaths (option to add codes to summary for summary care record)
- It Works ... (since used in our practice 85% of patients died in preferred place after template completed)

Non Cancer palliative patients

Patients Identified –
Long term condition reviews.
Frailty assessments
D1s / hospital letters
Adhoc





If Amber/Red or complex

* Involve GP +/- Macmillan services

Cancer Palliative patients

Patients Identified – Frailty assessments D1s / hospital letters Clinical meetings Adhoc



Initial Review by GP either in surgery (double appointment) or Home visit



Discuss oncology plan and letters if appropriate **Medication Review** Advanced care planning and DNACPR discussions if appropriate.

> Manage symptoms **GSF** category






GRFFN If stable / Green (ANP): *3 monthly reviews. *Involve appropriate resources (DN, SW, Dietician SALT Physio/OT,)





AMBER / RED GP continues care & Involve appropriate resources (DN / Macmillan)





Barnsley: Palliative Care (v1.0) AMENDED		
NICE guidance on Depression suggests that "screed depression in high-risk groups" and that "screening questions concerning mood and interest". During the last month, have you often been both During the last month, have you often been both depressions.	ACP ACP Continued Medication / MDT Meetings After Death ening should be undertaken in Primary Carefor for depression should include the use of at least two thered by feeling down, depressed or hopeless?	Depression screening using questions □ Date ▼ □ Checked □ □
things? Depression screening using questions		
A "yes" answer to either question is considered a pool of the test is positive, the patient should be further as This assessment should be informed by using a que HADS, or BDI, as used for the DEP2 indicator. To proceed to the PHQ-9 click the button below.	sessed for other symptoms.	No previous values
Barnsley: PHQ-9 Assessment (v2.0) Patient health questionnaire (PHQ-9) score		
Referral to GP		
Depression resolved		
Patient given advice about management of anxiety		
Patient given advice about management of depression		Show recordings from other templates Show empty recordings

Show Incomplete Fields










Where to find advice and guidance on Palliative care medications

BEST portal http://best.barnsleyccg.nhs.uk/



Click on Cancer, Palliative Care, Pain and Older People / Palliative care




Click on medicines Information / Prescribing guidelines


Prescribing anticipatory subcutaneous medications for the last days of life general advice (July 2016)

Indication	Drug	Dosing	Frequency	Strength	Quantity	Notes regarding syringe driver use
Pain - 1 st line (Doses may be different for patients already on background opioids and existing need should be considered) In renal failure ask specialist palliative care advice	Morphine Sulphate	2.5mg -5mg (if no existing opiate medication) If already taking oral morphine to calculate the sub cutaneous PRN dose calculate the 24 hour dose and divide by 6	2 hourly PRN	10mg/ml	10 x 1ml amps	If no existing opiates the syringe driver should only be used if PRNs have been required If converting from oral Morphine, use ½ of the 24hr oral Morphine dose in a syringe driver over 24 hours
Pain alternative to morphine	Oxycodone (alternative to morphine)	1mg - 2.5mg (if no existing opiate medication) If already taking oral morphine to calculate the sub cutaneous PRN dose calculate the 24 hour dose and divide by 6	2 hourly PRN	10mg/ml	5 x 1ml amps	If converting from oral Oxycodone to subcut use ½ of the 24 hour oral oxycodone in a syringe driver over 24 hours
Nausea, vomiting – 1 st line (Haloperidol also indicated for delirium, hallucinations and paranoia)	Haloperidol (extra pyramidal side effects and sedation in high doses)	0.5mg –1.5mg (max 5mg/24hr)	4 hourly PRN	5mg/ml	5 x 1ml amps	Syringe driver dose should be according to PRN need. Tendency to precipitate.
Nausea, vomiting (in Parkinson's disease or extrapyramidal side-effects)	Cyclizine (alternative to haloperidol for N+V)	50mg (max 150mg/24hr)	4-6 hourly PRN	50mg/ml	10 x 1ml amps	50-150mg in 24 hrs according to PRN need (maximum 150 mg)
Nausea, vomiting (Alternative if Haloperidol not available or appropriate or Haloperidol not effective)	Levomepromazine	6.25 mg	4-6 hourly PRN	25mg/1ml	5 x 1ml	Dose for syringe driver should be according to PRN use
Anxiety, restlessness, panic,	Midazolam	2.5mg-5mg (starting dose – if not effective speak to specialist palliative care)	hourly PRN	10mg/2mls	10 x 2ml amps	Syringe driver use will be according to PRNs used
Respiratory tract secretions	Hyoscine butylbromide (Buscopan)	20mg	2 hourly PRN	20mg/ml	10 x 1ml amps	If symptoms start syringe driver 60- 120mg/24hours Seek specialist palliative care if higher doses needed

EXAMPLES OF FP 10 PRESCRIPTIONS FOR ANTICIPATORY MEDICATIONS AND SYRINGE DRIVER IN END OF LIFE CARE



Pain (Morphine, Oxycodone)



Supporting information

- If further information is needed contact the Specialist Palliative Care Team
- If on a fentanyl patch maintain the patch, do not remove it and prescribe breakthrough opioid doses as attached guidance
- Please note a syringe driver may take up to 4 hours to become effective
- If patients have known renal failure, please contact the Specialist Palliative Care team for advice.

Converting from	То	Factor
Oral Morphine	Subcutaneous Morphine	Divide by 2
Oral Morphine	Subcutaneous Oxycodone	Divide by 3
Oral Oxycodone	Subcutaneous Oxycodone	Divide by 2

Weak Opioids	Usual Max 24 hour Dose	Dose of Morphine for continuous subcutaneous infusion via syringe driver over 24 hours	Dose of subcutaneous <mark>Morphine</mark> for breakthrough
Tramadol	400mg	10mg - 20mg	2.5mg – 5mg
Codeine Phosphate	240mg	10mg	2.5mg – 5mg

For alternative step 2 conversions, e.g. BuTrans, Transtec Please seek Specialist Palliative Care advice

Fentanyl patch in situ


Do not remove the patch as this will complicate management

- Ensure that patch is adherent to patient's skin.
- · Reassess patient to identify any other causes for increased pain.
- Continue to change patch every 72 hours.
- If pain is uncontrolled commence subcutaneous infusion of opioid in addition to Fentanyl patch according to the PRN doses that have been required
- Administer breakthrough analgesia as required according to dose regime below.

Transdermal <mark>Fentanyl Patch</mark> currently in use	Breakthrough doses of subcutaneous <mark>Morphine</mark> when Fentanyl Patch in use only
12mcg	2.5-5mg
25mcg	5-10mg
50mcg	10-15mg
75mcg	15-20mg
100mcg	20-30mg

Adapted from: PCF4 Palliative Care Formulary (2011) Contact Specialist Palliative Care Team for additional advice if required

Nausea and vomiting (Haloperidol, Cyclizine, Levopromazine)




Supportive information

- If symptoms persist or further advice is needed contact the Specialist Palliative Care Team
- HALOPERIDOL is not recommended for patients with Parkinson's Disease, first line Cyclizine would be suggested.
- For alternative anti-emetics see Palliative Care Formulary or contact the Specialist Palliative Care team.
- If HALOPERIDOL is not available or ineffective, consider Levomepromazine.

Last days of life symptom management guidance


Agitation, delirium and anxiety (Midazolam and Haloperidol)



Supportive information


- HALOPERIDOL is not recommended for patients with Parkinsons Disease, in this case use MIDAZOLAM or seek Specialist Care advice.
- Please be aware that MIDAZOLAM can cause a paradoxical increase in agitation, in this instance use HALOPERIDOL
- If symptoms persist or any further advice is peeded contact the appropriate Specialist Palliative Care team

Respiratory tract secretions (Hyoscine butylbromide)



 Consider changing or stopping medicines if noisy respiratory secretions continue after 12 hours (medicines may take up to 12 hours to become effective)

Dyspnoea (Midazolam and Morphine lower dose and this needs to be specific on the drug chart for dyspnoea)



Supportive information

- An alternative to Midazolam would be to use low dose subcutaneous Morphine 1.25mg 2.5mg this may be more useful in patients with heart failure.
- . If symptoms persist, contact Specialist Palliative Care team.
- Identify and treat reversible causes of breathlessness in the dying person, for example pulmonary oedema or pleural effusion.
- Consider non- pharmacological management of breathlessness in a person in the last days of life. Do not routinely start oxygen to manage breathlessness. Only offer oxygen therapy to people known or clinically suspected to have symptomatic hypoxaemia.

Contact numbers

- Community Macmillan Service Advice Line
 01226 644755 (Mon Fri 9am 5pm)
 01226 644575 (weekend and bank holidays)
- Rapid Response
 07747 794698 (Evening and night)
- i-Heart 365 Out of hours GP service
 01226 242471
- Pall Call advice for health care professionals
 01226 244244